+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Malignant Mesothelioma Market by Treatment Type, Drug Class, Line of Therapy, Route of Administration, End User - Global Forecast to 2030- Product Image
Malignant Mesothelioma Market by Treatment Type, Drug Class, Line of Therapy, Route of Administration, End User - Global Forecast to 2030- Product Image
Sale

Malignant Mesothelioma Market by Treatment Type, Drug Class, Line of Therapy, Route of Administration, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 188 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889052
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Malignant Mesothelioma Market grew from USD 834.43 million in 2024 to USD 905.16 million in 2025. It is expected to continue growing at a CAGR of 8.32%, reaching USD 1.34 billion by 2030.

Unveiling the Complexity of Malignant Mesothelioma

Malignant mesothelioma presents a formidable challenge to the global healthcare community, characterized by its aggressive progression and resistance to many conventional therapies. Often linked to asbestos exposure, this rare malignancy primarily affects the mesothelial lining of the lungs, abdomen, and heart, imposing a severe burden on patients and caregivers alike. Despite advancements in diagnostic imaging and histopathological techniques, early detection remains elusive, complicating efforts to intervene before the disease advances beyond curative thresholds.

In recent years, the intersection of scientific discovery and clinical innovation has begun to transform the therapeutic landscape. Novel immunotherapeutic approaches and refined surgical techniques are gradually improving survival outcomes, while multidisciplinary care pathways are enhancing quality of life for those affected. Simultaneously, shifting regulatory priorities and evolving reimbursement frameworks are influencing market access and the pace of product launches. This executive summary synthesizes critical insights into these developments, offering a concise yet comprehensive overview of the current state of mesothelioma treatment, the forces driving change, and the strategic imperatives for stakeholders committed to advancing patient care.

Emerging Paradigms Reshaping Treatment and Market Dynamics

The mesothelioma landscape is undergoing profound transformation as breakthroughs in immunology and molecular biology converge with precision medicine initiatives. Therapies that harness the body’s own immune defenses are rapidly gaining traction, displacing traditional monotherapies with combination regimens that target multiple pathways simultaneously. Concurrently, the integration of genomic profiling into routine clinical practice is enabling the identification of novel biomarkers and personalized treatment strategies, creating opportunities for agents that modulate tumor microenvironments or interrupt specific signaling cascades.

Beyond the lab, digital health platforms and real-world evidence are reshaping how clinical outcomes are measured and how safety signals are monitored post-launch. Data analytics powered by machine learning are streamlining patient stratification and accelerating trial enrollment, while cloud-based registries foster collaboration among academic centers, industry sponsors, and regulatory bodies. Together, these shifts are redefining value propositions, compelling biopharma companies and providers to adopt agile development frameworks and collaborative commercial models that align with the demands of payers and patients alike.

Assessing the Ripple Effects of U.S. Tariffs in 2025

Recent imposition of U.S. tariffs on critical import components has generated considerable headwinds for manufacturers and providers in the mesothelioma treatment sector. The 2025 tariff schedule, targeting active pharmaceutical ingredients and specialized delivery systems, has elevated production costs and squeezed profit margins across the supply chain. In response, several stakeholders have accelerated localization efforts, forging partnerships with domestic suppliers to mitigate cost inflation and ensure continuity of critical drug availability.

However, these strategic adjustments carry their own set of challenges. The transition to new manufacturing sites necessitates rigorous validation protocols and extended regulatory review periods, which could delay time to market for promising therapies. At the same time, higher acquisition costs are translating into upward pressure on pricing, prompting payers to scrutinize value claims more intensely. As a result, companies must balance cost containment with compelling clinical differentiation to justify premium positioning in an increasingly cost-sensitive environment.

Decoding Market Segmentation for Strategic Clarity

Market segmentation analysis reveals that treatment type remains a cornerstone for strategic planning, with chemotherapy regimens dissected into pemetrexed combinations and platinum monotherapy, while immunotherapy is advancing through Ctla-4 and Pd-1 inhibitors. Radiotherapy and surgical interventions continue to serve as critical pillars of standard care, even as targeted agents such as Egfr inhibitors, mesothelin-directed therapies and Vegf inhibitors surge into clinical practice. Equally important, class-level evaluation underscores the role of antifolates, immune checkpoint inhibitors encompassing Ctla-4, Pd-1 and Pd-l1 targets, kinase inhibitors, monoclonal antibodies and platinum compounds in shaping treatment algorithms.

Beyond pharmacological dimensions, the line-of-therapy framework segments first-line, second-line and third-line and beyond interventions, illuminating pathways for optimizing sequencing strategies. Pharmacokinetic and patient preference considerations drive contrasting adoption patterns across intraperitoneal, intravenous and oral administration routes. Finally, end-user distinctions among ambulatory surgical centers, hospitals and specialty clinics highlight distribution nuances and service model variations that influence market penetration and patient access.

Geographical Hotspots Driving Market Variance

Regional performance in malignant mesothelioma therapy reflects a patchwork of healthcare infrastructures, regulatory environments and reimbursement policies. In the Americas, robust private sector investment and well-established oncology networks support rapid uptake of novel modalities, although payer consolidation and cost-containment pressures are fostering tougher negotiation dynamics. Europe, Middle East & Africa present a mosaic of market maturity, with Western European nations pioneering accelerated approval pathways and centralized procurement, while emerging and resource-constrained markets in Eastern Europe, the Middle East and Africa grapple with infrastructure gaps and supply chain disruptions.

In the Asia-Pacific region, demographic trends and rising healthcare expenditure underpin strong demand for innovative therapies, yet heterogeneity in regulatory alignment and clinical trial capacity creates entry barriers. Collaborative initiatives aimed at harmonizing standards and expanding local trial sites are gradually enhancing market attractiveness. Overall, regional insights emphasize the necessity for tailored market access strategies that reconcile global evidence with localized healthcare priorities and stakeholder expectations.

Profiling Pioneers and Innovators in the Field

The competitive landscape of mesothelioma therapeutics is marked by a blend of established pharmaceutical giants and nimble biotech innovators. Leading players have leveraged expansive pipelines and global distribution networks to secure early mover advantages in immunotherapy and targeted agent segments, while emerging companies focus on next-generation modalities such as bispecific antibodies and oncolytic viruses. Strategic alliances and licensing agreements continue to proliferate, enabling smaller organizations to access development expertise, clinical trial infrastructure and commercialization capabilities.

Several key entrants have distinguished themselves through differentiated mechanisms of action and patient enrollment strategies, driving accelerated adoption in specialized treatment centers. Meanwhile, contract manufacturing and research organizations are capitalizing on outsourcing trends, offering turnkey services that expedite scale-up and regulatory compliance. Collectively, these dynamics underscore a vibrant ecosystem in which innovation, collaboration and strategic positioning coalesce to define market leadership.

Strategic Imperatives to Seize Future Opportunities

Industry leaders must prioritize the integration of real-world evidence into clinical and commercial strategies, leveraging patient registries and digital health tools to substantiate value propositions and negotiate favorable reimbursement terms. Investing in adaptive clinical trial designs can reduce time-to-market for breakthrough therapies, while public-private partnerships offer pathways to share risk and enhance trial accessibility across disparate geographies. Furthermore, companies should explore modular manufacturing platforms to enhance supply chain resilience and respond swiftly to tariff-induced cost fluctuations.

On the commercial front, stakeholder engagement must extend beyond payers to encompass patient advocacy groups and multidisciplinary care teams, ensuring that market access frameworks reflect the holistic needs of patients. Upskilling field teams in health economics and outcomes research will be critical for articulating differentiated value stories, and digital outreach initiatives can amplify educational efforts among prescribers and patients. By aligning strategic investments with emerging market dynamics, organizations can unlock sustained growth and foster meaningful improvements in patient outcomes.

Robust Approach to Data Collection and Analysis

This analysis is grounded in a multi-source research approach, combining primary interviews with key opinion leaders across oncology and pharmacoeconomics, in-depth consultations with biopharma executives and insights from regulatory filings. Secondary research encompassed peer-reviewed journals, conference proceedings and publicly available clinical trial registries to validate therapeutic efficacy and safety profiles. Quantitative data underpinning segmentation and regional analysis were calibrated against proprietary databases and cross-referenced with industry benchmarks to ensure robustness.

Rigorous data triangulation and thematic coding methods were applied to qualitative inputs, enabling coherent synthesis of stakeholder perspectives. All findings were subjected to peer review by subject matter experts to mitigate bias and enhance credibility. This methodology ensures that the insights presented are both comprehensive and reflective of the latest advancements in malignant mesothelioma research and market development.

Synthesis of Insights and Strategic Outlook

The insights distilled in this executive summary reveal a mesothelioma landscape defined by rapid innovation, complex market access dynamics and regional diversity. As immunotherapeutic regimens and targeted therapies gain momentum, stakeholders must navigate evolving reimbursement frameworks and supply chain challenges exacerbated by tariff shifts. Strategic segmentation provides clarity on treatment sequencing and distribution channels, while regional analysis underscores the necessity of customized access strategies.

Looking ahead, companies that harness real-world evidence, embrace flexible development models and cultivate collaborative ecosystems will be best positioned to deliver transformative therapies. By aligning scientific ambition with patient-centric value frameworks, the industry can accelerate progress against this aggressive malignancy and secure sustainable growth in an increasingly competitive environment.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Chemotherapy
      • Pemetrexed Combinations
      • Platinum Monotherapy
    • Immunotherapy
      • Ctla-4 Inhibitors
      • Pd-1 Inhibitors
    • Radiotherapy
    • Surgery
    • Targeted Therapy
      • Egfr Inhibitors
      • Mesothelin Targeted Agents
      • Vegf Inhibitors
  • Drug Class
    • Antifolates
    • Immune Checkpoint Inhibitors
      • Ctla-4 Inhibitors
      • Pd-1 Inhibitors
      • Pd-l1 Inhibitors
    • Kinase Inhibitors
    • Monoclonal Antibodies
    • Platinum Compounds
  • Line Of Therapy
    • First Line
    • Second Line
    • Third Line And Beyond
  • Route Of Administration
    • Intraperitoneal
    • Intravenous
    • Oral
  • End User
    • Ambulatory Surgical Centers
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Malignant Mesothelioma Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.2.1. Pemetrexed Combinations
8.2.2. Platinum Monotherapy
8.3. Immunotherapy
8.3.1. Ctla-4 Inhibitors
8.3.2. Pd-1 Inhibitors
8.4. Radiotherapy
8.5. Surgery
8.6. Targeted Therapy
8.6.1. Egfr Inhibitors
8.6.2. Mesothelin Targeted Agents
8.6.3. Vegf Inhibitors
9. Malignant Mesothelioma Market, by Drug Class
9.1. Introduction
9.2. Antifolates
9.3. Immune Checkpoint Inhibitors
9.3.1. Ctla-4 Inhibitors
9.3.2. Pd-1 Inhibitors
9.3.3. Pd-l1 Inhibitors
9.4. Kinase Inhibitors
9.5. Monoclonal Antibodies
9.6. Platinum Compounds
10. Malignant Mesothelioma Market, by Line of Therapy
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line and Beyond
11. Malignant Mesothelioma Market, by Route of Administration
11.1. Introduction
11.2. Intraperitoneal
11.3. Intravenous
11.4. Oral
12. Malignant Mesothelioma Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Americas Malignant Mesothelioma Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Malignant Mesothelioma Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Malignant Mesothelioma Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bristol-Myers Squibb Company
16.3.2. Eli Lilly and Company
16.3.3. AstraZeneca PLC
16.3.4. Merck & Co., Inc.
16.3.5. F. Hoffmann-La Roche Ltd.
16.3.6. Pfizer Inc.
16.3.7. Johnson & Johnson
16.3.8. Novartis AG
16.3.9. Takeda Pharmaceutical Company Limited
16.3.10. Sanofi S.A.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MALIGNANT MESOTHELIOMA MARKET MULTI-CURRENCY
FIGURE 2. MALIGNANT MESOTHELIOMA MARKET MULTI-LANGUAGE
FIGURE 3. MALIGNANT MESOTHELIOMA MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MALIGNANT MESOTHELIOMA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 64. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 66. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 67. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 68. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 69. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 70. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 71. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. CANADA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 75. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 76. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 77. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 78. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 79. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 80. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. MEXICO MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 107. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 112. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 114. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 115. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 116. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 117. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. UNITED KINGDOM MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 119. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 121. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 122. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 123. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 125. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 126. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. GERMANY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 129. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 130. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 131. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 132. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 133. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 134. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 135. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. FRANCE MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 139. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 140. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 141. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 143. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 144. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 145. RUSSIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 148. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 149. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 150. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 151. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 152. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 153. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. ITALY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 156. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 157. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 158. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 159. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 160. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 162. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. SPAIN MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 166. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 167. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 168. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 169. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 170. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 171. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. UNITED ARAB EMIRATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 175. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 176. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 177. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 186. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 188. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 189. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 190. SOUTH AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 192. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 193. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 194. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 195. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 198. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 199. DENMARK MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 204. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 205. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 206. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 207. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. NETHERLANDS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 210. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 212. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 213. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 214. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 215. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 216. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. QATAR MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 219. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 220. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 221. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 222. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 223. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 224. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 225. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. FINLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 229. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 230. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 231. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 233. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 234. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. SWEDEN MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 238. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 247. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 248. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 249. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 250. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 251. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 252. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 253. EGYPT MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 254. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 255. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 256. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 257. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 258. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 259. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 260. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 261. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 262. TURKEY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 265. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 266. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 267. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 268. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 269. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 270. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. ISRAEL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 273. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 274. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 275. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 276. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 277. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 278. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 279. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 280. NORWAY MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 281. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 282. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 283. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 284. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 285. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 286. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 287. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 288. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. POLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 291. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 292. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 293. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 294. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 295. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 296. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 297. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 298. SWITZERLAND MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 299. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 300. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 301. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 302. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 303. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 304. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 305. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 306. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 307. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 309. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 310. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 311. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 312. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 313. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 314. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 315. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 316. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 319. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
TABLE 320. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
TABLE 321. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
TABLE 322. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 323. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2030 (USD MILLION)
TABLE 324. INDIA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 325. INDIA MA

Companies Mentioned

The companies profiled in this Malignant Mesothelioma market report include:
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Sanofi S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages188
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 905.16 Million
Forecasted Market Value ( USD ) by 2030 $ 1340 Million
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Malignant Pleural Mesothelioma Market (2024 Edition): Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030) - Product Image

Malignant Pleural Mesothelioma Market (2024 Edition): Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)

  • Report
  • 259 Pages
  • Global
From
Malignant Mesothelioma - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Malignant Mesothelioma - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Malignant Mesothelioma - Global Strategic Business Report - Product Image

Malignant Mesothelioma - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Mesothelioma - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Mesothelioma - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Malignant Mesothelioma Therapeutics Market Report and Forecast 2024-2032 - Product Image

Malignant Mesothelioma Therapeutics Market Report and Forecast 2024-2032

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.